Neurotrope, Inc. (NasdaqCM:NTRP) announced its plans to explore strategic alternatives to maximize shareholder value. Charles S. Ryan, Chief Executive Officer, stated that "Following the results from our Phase 2 study of Bryostatin-1 in Alzheimer's disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value". "The Board of Directors has formed a strategic alternatives committee to aid in evaluating the Company's alternatives, and we look forward to providing an update when appropriate." There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome. The Company does not intend to comment further or publicly discuss the potential of alternate developments unless and until its Board of Directors has approved a definitive transaction, or otherwise determined that further disclosure is appropriate or required by law. Moreover, the Company is continuing to determine how to proceed with respect to the Company's current development programs for Bryostatin-1 in its effort to maximize shareholder value.